GLP-1 Receptor Agonists in Diabetes and Beyond 2024

** Please note this program was featured in OPSC's 35th Annual Fall Conference, CME by the Bay 2024, held in Monterey, California. If you attended this event in person or purchased the digital edition, you will not qualify for CME credits by participating in the program. ** 

In this session, we will delve into the how, when, and why these agents are used in a range of health conditions. The GLP-1RA has fundamentally transformed diabetes treatment, now being utilized for both recommended and off-label indications, with more applications on the horizon. 

Learning Objectives:

• Review the direct and pleiotropic effects of incretin-based agonism.
• Explore current and future incretin-based agents.
• Discuss current and future health benefits in diabetes, obesity, kidney disease, heart disease, and cognition.

Disclosures: 

I have clinical trials with Eli Lilly and Bayer. I have served as an advisor or consultant with Abbott, Bayer, Eli Lilly, Madrigal, Novo Nordisk. I am involved in the guidelines for the American Diabetes Association (ASOC), Consensus Statement on Diabetes and Liver Disease, 2025 SOC and American Gastroenterology Association, 2021 Guidelines for NAFLD/NASH, 2025 Guidelines for MASLD/MASH.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Osteopathic Association (AOA). The Osteopathic Physicians and Surgeons of California (OPSC) is accredited by the AOA to provide osteopathic continuing medical education for physicians. 

Grievance Policy: Osteopathic Physicians and Surgeons of California (OPSC) strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Uniform Guidelines and AOA Accreditation Requirements. Comments, questions, or complaints should be forwarded to OPSC, by calling the OPSC Office at (916) 822-5246 or by email at opsc@opsc.org.